Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600135020) titled 'A Single-Center, Randomized, Blinded, Adjuvant- and Placebo-Controlled Phase ? Clinical Trial to Evaluate the Safety and Tolerability and Preliminarily Explore the Immunogenicity of a Split Influenza Virus Vaccine (CpG Adjuvant) in Adults Aged 18 Years and Older' on Oct. 23.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Hebei Center for Disease Control and Prevention

Condition: The main influenza (flu)

Intervention: The experimental group (low-dose or high-dose):Receiving one dose of the trial vaccine, the hemagglutinin content of each type of influenza virus was 15 µg, and ...